Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2965501 Monotherapy and Combination in Advanced Solid Tumors
NCT05614102Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of veludacigib in solid tumor (advanced stage) (6 arms), sponsored by Bayer. Primary endpoints: Treatment-Emergent Adverse Events, Maximum Tolerated Dose and 3 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
veludacigib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05614102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614102.